2020 American Transplant Congress
Utilization of Hepatitis C Viremic Donors in Liver Transplantation. A Single Center Experience
*Purpose: The evolution of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), in the setting of the well recognized organ shortage and the…2020 American Transplant Congress
Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…2020 American Transplant Congress
Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center
Duke University Medical Center, Durham, NC
*Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…2020 American Transplant Congress
Adult Primary Liver Transplant Recipient Outcomes by Immunosuppression Induction Received
*Purpose: It has long been recognized that the highest risk of rejection of an organ is in the first few months post transplantation. To prevent…2020 American Transplant Congress
Waitlist Times, Hospital Length of Stay, and Immediate Post-Operative Outcomes of HCV Positive Donors in HCV Negative Liver and Kidney Transplant Recipients
*Purpose:Introduction The advent of direct-acting antivirals (DAAs) has significantly changed liver and kidney transplantation for patients with chronic hepatitis C (HCV) infection. Successful and relatively…2020 American Transplant Congress
Highly Effective Short Course Therapy to Prevent Infection after Transplantation from HCV-Infected Organ Donors to Uninfected Recipients across Multiple Organ Types
*Purpose: An increasing percentage of potential organ donors are infected with hepatitis C virus (HCV). Establishment of HCV infection in uninfected recipients is near-universal with…2020 American Transplant Congress
Does Transplantation of Hepatitis C Infected Kidneys Into Uninfected Recipients Cause Hepatitis C-Associated Kidney Injury?
Vanderbilt University Medical Center, Nashville, TN
*Purpose: With increasing utilization of Hepatitis C infected (HCV+) kidneys for transplantation into uninfected (HCV-) recipients, there is concern for the development of HCV-associated kidney…2020 American Transplant Congress
Association between Ezetimibe Usage and Hepatitis C RNA Levels in Uninfected Kidney Transplant Recipients Who Received Hepatitis C Infected Kidneys
James D. Eason Transplant Institute, Methodist University Hospital, Memphis, TN
*Purpose: Our previous data showed that transplantation of kidneys from hepatitis C virus (HCV) infected donors to HCV negative recipients achieved excellent short-term graft function,…2020 American Transplant Congress
Feasibilty of Hepatitis C NAT Positive Kidney Transplant into Hepatitis C Negative Recipients as Standard of Care
University of Cincinnati Medical Center, Cincinnati, OH
*Purpose: With advent of direct acting antivirals (DAA) for Hepatitis (Hep) C which have a 96-100% sustained viral remission(SVR), doors have opened for using Hep…2020 American Transplant Congress
Fibrosing Cholestatic Hepatatitis in Post Renal Transplant and Successful Treatment with Newer DAA Therapy
Nephrology, Manipal Hospital, Bangalore, India
*Purpose: Fibrosing cholestatic hepatitis is often fatal post renal transplantation. we report a case of successful treatment of FCH and complete recovery*Methods: A 53 year…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 28
- Next Page »